CN115400050A - 包含天山雪莲、松萝及发酵黑参提取物的抗老化用组合物 - Google Patents
包含天山雪莲、松萝及发酵黑参提取物的抗老化用组合物 Download PDFInfo
- Publication number
- CN115400050A CN115400050A CN202110796892.0A CN202110796892A CN115400050A CN 115400050 A CN115400050 A CN 115400050A CN 202110796892 A CN202110796892 A CN 202110796892A CN 115400050 A CN115400050 A CN 115400050A
- Authority
- CN
- China
- Prior art keywords
- extract
- aging
- usnea
- skin
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 129
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 241000006302 Usnea Species 0.000 title claims abstract description 41
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 28
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims abstract description 44
- 235000020710 ginseng extract Nutrition 0.000 claims abstract description 44
- 230000000694 effects Effects 0.000 claims abstract description 39
- 241000133134 Saussurea Species 0.000 claims abstract description 37
- 238000004132 cross linking Methods 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 24
- 230000009759 skin aging Effects 0.000 claims abstract description 20
- 230000032677 cell aging Effects 0.000 claims abstract description 18
- 230000036542 oxidative stress Effects 0.000 claims abstract description 14
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract 3
- 208000002249 Diabetes Complications Diseases 0.000 claims abstract 3
- 206010012655 Diabetic complications Diseases 0.000 claims abstract 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract 3
- 201000006370 kidney failure Diseases 0.000 claims abstract 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 238000003776 cleavage reaction Methods 0.000 claims description 17
- 230000007017 scission Effects 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 238000005520 cutting process Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 abstract description 35
- 108010035532 Collagen Proteins 0.000 abstract description 35
- 229920001436 collagen Polymers 0.000 abstract description 35
- 239000003814 drug Substances 0.000 abstract description 5
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 2
- 230000003013 cytotoxicity Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 37
- 240000004371 Panax ginseng Species 0.000 description 34
- 235000008434 ginseng Nutrition 0.000 description 34
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 31
- 235000003140 Panax quinquefolius Nutrition 0.000 description 31
- 230000032683 aging Effects 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 210000002950 fibroblast Anatomy 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000000605 extraction Methods 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 244000005700 microbiome Species 0.000 description 11
- -1 or the like Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 241000193830 Bacillus <bacterium> Species 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 239000004375 Dextrin Substances 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 235000019425 dextrin Nutrition 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000037394 skin elasticity Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 235000002789 Panax ginseng Nutrition 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000002421 anti-septic effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000003810 hyperpigmentation Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000000419 plant extract Substances 0.000 description 5
- 239000012264 purified product Substances 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000006468 Thea sinensis Nutrition 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 235000020279 black tea Nutrition 0.000 description 4
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229940032094 squalane Drugs 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 239000007766 cera flava Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 230000037373 wrinkle formation Effects 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241001513093 Aspergillus awamori Species 0.000 description 2
- 241000122821 Aspergillus kawachii Species 0.000 description 2
- 240000006439 Aspergillus oryzae Species 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 2
- 241000131386 Aspergillus sojae Species 0.000 description 2
- 241001112078 Aspergillus usamii Species 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000320412 Ogataea angusta Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 241001145025 Saussurea involucrata Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 241000235015 Yarrowia lipolytica Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 108010028309 kalinin Proteins 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 241000511582 Actinomyces meyeri Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000296825 Amygdalus nana Species 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 244000304217 Brassica oleracea var. gongylodes Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 240000008955 Dioscorea japonica Species 0.000 description 1
- 235000005251 Dioscorea japonica Nutrition 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 240000007890 Leonurus cardiaca Species 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000294180 Osmunda japonica Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 241001264038 Usnea diffracta Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- MKOMESMZHZNBIZ-UHFFFAOYSA-M alagebrium Chemical compound [Cl-].CC1=C(C)SC=[N+]1CC(=O)C1=CC=CC=C1 MKOMESMZHZNBIZ-UHFFFAOYSA-M 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/09—Lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9733—Lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Birds (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
本发明涉及包含天山雪莲提取物、松萝提取物、发酵黑参提取物的混合物作为有效成分的抗老化或晚期糖基化终产物相关疾病的预防、改善或治疗用组合物。作为上述组合物中所含的有效成分的天山雪莲提取物、松萝提取物及发酵黑参提取物的混合物，抑制因氧化应激引起的细胞老化，切割晚期糖基化终产物AGEs(Advanced glycat ion end‑products)与胶原蛋白之间的交联，由此可预防、改善及治疗皮肤老化，并可预防、改善及治疗糖尿病并发症、动脉硬化、肾功能衰竭、类风湿性关节炎及阿尔茨海默病等晚期糖基化终产物相关疾病。并且，上述混合物没有细胞毒性及人体副作用，由此可安全地适用于化妆品、食品、医药品及外用剂组合物。
Description
技术领域
本发明涉及包含植物提取物作为有效成分的抗老化用组合物，具体地涉及包含天山雪莲提取物、松萝提取物、发酵黑参提取物的复合物作为有效成分，同时具有因氧化应激引起的细胞老化抑制效果及晚期糖基化终产物AGEs(Advanced glycation end-products)与胶原蛋白之间的交联切割效果，不仅可有效改善皮肤老化，而且预防或改善因AGEs蓄积引起的皮肤皱纹生成。皮肤弹性减少、皮肤炎症增加、色素沉着过度的抗老化用组合物。
背景技术
皮肤是老化主要出现的器官，为了延迟或预防老化，在化妆品领域中也进行多项研究。通常，皮肤老化从25岁左右开始进行，到了40岁左右皮肤老化正式进行。皮肤的老化分为光老化和内源性老化，对于内源性老化而言，其为随着年龄增长，与时间的经过成正比例而引起的退化性变化即自然现象。与皮肤老化相关的皮肤的外在形态变化有皮肤干燥、皮肤下垂及皱纹等，皮肤疾病有脂溢性角化病或黑点等。作为根据皮肤老化而在皮肤各层引起的现象，因真皮内包含胶原蛋白、GAG的细胞外基质(ECM，extracellular matrix)生成的减少而使真皮萎缩，皮肤表皮也变薄，干燥。负责真皮和表皮接合的表皮-真皮接合部(DEJ，Dermal epidermal junction)蛋白质也是随着老化的进行，表达减少，表皮-真皮接合部平坦，连接变差，皮肤容易受损，不能顺利供给营养，由此促进皮肤老化。并且，即使因紫外线之类的外部因素也会减少。作为DEJ相关蛋白质有胶原蛋白4(coll agen 4)、胶原蛋白7(collagen 7)、胶原蛋白17(collagen 17)、层粘连蛋白5(Laminin 5)。作为外源性老化的代表性诱发因子的活性氧产生在紫外线、公害、炎症以及细胞自身代谢过程中，起到促进细胞老化的作用。
并且，根据糖化反应(美拉德反应(Maillard reaction)，Glycation)生成的晚期糖基化终产物与胶原蛋白的异常交联也与皮肤老化密切相关。糖化反应是根据还原糖的羰基(carbonyl)和作为蛋白质的游离氨基(amino)的赖氨酸(lysine)或精氨酸(arginine)的非酶反应，形成初期步骤的产物席夫碱(shiff base)，继续通过缩合、再移位、氧化、分裂、环化等一系列复杂的反应，形成褐色的不可逆晚期糖基化终产物(Advanced glycationend-products，AGEs)的过程。
据悉，作为这种不可逆反应产物的晚期糖基化终产物，一旦生成就不被分解，与晶体蛋白、胶原蛋白(Collagen)等进行交联(Cros slinking)，蓄积于皮肤或组织，将其结构和功能异常改变，由此与多种皮肤老化现象相关联。尤其，已在多项研究中报告，晚期糖基化终产物与皮肤皱纹形成等老化相关的多种疾病的进行过程密切相关(SeminNephrol.2007Mar；27(2):130-43；及Curr Alzheimer Res.2004Feb；1(1):39-46)。据悉，代表性的是，与胶原蛋白交联(cross-linking)而生成的晚期糖基化终产物蓄积于皮肤，诱导皮肤的弹性减少及皱纹，这些晚期糖基化终产物的半衰期比起一般细胞的平均半衰期长2倍左右，在成纤维细胞等皮肤细胞中也诱导损伤。与其类似的研究表明，当晚期糖基化终产物以增加的浓度存在时，老鼠(Rats)的胶原蛋白微丝中观察到异常的结构变化(Odetti P,Aragno I,et al.Gerontology,1998,44(4)；187-91)。据悉，作为另一种皮肤老化的外观变化的老年斑是因皮肤老化而形成的皮肤上的寿斑，其因素也与晚期糖基化终产物的蓄积密切相关(Lee EJ,et al.Sci Rep.,2016,6:27848)。
若促进细胞老化，则导致细胞再生力和胶原蛋白、弹性蛋白、透明质酸等皮肤组成物质的合成能力降低。不仅如此，基于老化的生长因子受体(growth factor receptor)减少导致对于外部生长因子的反应性降低，激活细胞的生长因子无法正常起作用的情况较多。实际上，继续报告如下研究结果，对于细胞老化进行的成纤维细胞而言，针对代表性的皮肤活性因子EGF(表皮生长因子，epidermal growth factor)的受体减少，即使处理EGF也不呈现反应(Hidenori Shiraha et al,JBC,275；19343-19351,2000)。因此，为了与EGF之类的细胞活性因子适当反应，可类推抑制细胞老化是主要的抗老化用战略。
根据以往研究报告，在正常生理条件下，β-淀粉样蛋白缓慢凝集，与此相反，根据与晚期糖基化终产物之间的交联而变形的β-淀粉样蛋白(AGE-modifiedβ-amyloid)快速凝集(Neurobiology,91,4766-4770,1994)。
对此，本发明人为了开发将稳定性及安全性高而没有皮肤副作用的天然来源化合物作为对象，可同时抑制表皮-真皮接合部(DEJ)及真皮细胞的老化的抗老化用组合物，继续研究的结果发现如下事实，天山雪莲提取物、松萝提取物、发酵黑参提取物的复合物可同时呈现因氧化应激引起的细胞老化抑制效果及晚期糖基化终产物AGEs(Advancedglycation end-products)与胶原蛋白之间的交联切割效果，由此完成本发明。
现有技术文献
非专利文献
(非专利文献0001)Tan AL,et al.,Semin Nephrol.,27(2):130-43,2007
(非专利文献0002)Takeuchi M,et al.,Curr Alzheimer Res.,1(1):39-46,2004
(非专利文献0003)Odetti P,et al.,Gerontology.,44(4):187-91,1998
(非专利文献0004)Shiraha H,et al.,J Biol Chem.,275(25):19343-51,2000
(非专利文献0005)Lee EJ,et al.,Sci Rep.,6:27848,2016
发明内容
要解决的问题
本发明的一目的在于，提供包含天山雪莲提取物、松萝提取物及发酵黑参提取物作为有效成分，同时具有因氧化应激引起的细胞老化抑制效果及晚期糖基化终产物AGEs(Advanced glycation end-products)与胶原蛋白之间的交联切割效果，并可有效预防或改善皮肤老化的抗老化用组合物。
本发明的另一目的在于，提供将包含天山雪莲提取物、松萝提取物及发酵黑参提取物作为有效成分的组合物给药到对象，同时表达因氧化应激引起的细胞老化抑制效果及晚期糖基化终产物AGEs(Advanced glycation end-products)与胶原蛋白之间的交联切割效果，由此预防或改善皮肤老化的方法。
解决问题的方案
作为一个实施方式，本发明涉及包含天山雪莲提取物、松萝提取物、发酵黑参提取物的复合物作为有效成分的抗老化组合物。
在本发明中，天山雪莲(Saussurea Involucrata)是菊花科的植物，其生长在喜马拉雅和东亚的高山栖息地。高5～10cm至3m，叶子密集，并呈薇花型生长，花茎呈螺旋型上升。花开在夏季和秋季，其是陡峭的悬崖上生长的稀有药用植物，被认为维吾尔族的传统药材。
在本发明中，松萝(Usnea diffracta)是属于梅树地衣科松萝属的地衣类，茎部非常长，叶枝非常短。发现在欧洲、亚洲、北美的北方森林(泰加森林)，中医里使用为利尿剂、解热剂、祛痰剂。
在本发明中，术语“提取物”是指将植物或生药提取为适当的浸出液，蒸发浸出液而浓缩的原材料，虽然并不限定于此，但是可以是通过提取处理而获得的提取液、提取液的稀释液或浓缩液、干燥提取液而获得的干燥物、它们的粗纯化物或纯化物。
上述提取物可利用本领域公知的提取方法及提取溶剂来获得。上述提取溶剂虽然不是务必限定于此，但是可使用水、碳原子数1至4的无水或含水低级醇(甲醇、乙醇、丙醇、丁醇等)、上述低级醇与水的混合溶剂、丙酮、乙酸乙酯、氯仿或1,3-丁二醇中的任一个溶剂。优选地，利用甲醇、乙醇或丁醇提取为宜。根据提取的有机溶剂，提取物的有效成分的提取程度和损失程度会出现差异，因此优选地选择适当有机溶剂来使用。作为上述提取方法有冷浸提取、超声波提取或回流冷却提取方法等，不特别限定于此。
并且，上述提取物除了根据上述提取溶剂提取的方法以外，还可经过常规纯化过程获得。例如，通过利用具有规定的分子量临界值的超过滤膜的分离、基于多种层析(为了基于大小、电荷、疏水性或亲和性的分离而制作)的分离等追加实施的多种纯化方法获得分馏物，通过这些分馏物也能获得提取物。
作为一个具体例，对于天山雪莲提取物而言，对天山雪莲的叶、花、茎部或根部，或者它们的组合进行阴干并研磨之后干燥的样品的重量的0.5至20倍，优选地以1至15倍分量的水、乙醇、甲醇等C1至C4的低级醇或水和乙醇以1:0.1至1:10，优选地以1:0.2至1:9的混合比(kg/l)混合的混合溶剂，在50～80℃下使用搅拌提取、热水提取、冷浸提取、回流冷却提取或超声波提取等提取方法提取约0.5至48小时，优选地提取1至30小时之后获得提取液，对该提取液进行过滤、减压浓缩或干燥，由此可获得天山雪莲提取物。
作为另一具体例，对于松萝提取物而言，对雪莲的地衣体或整体部位进行阴干并研磨之后干燥的样品的重量的0.5至20倍，优选地以1至15倍分量的水、乙醇、甲醇等C1至C4的低级醇或水和乙醇以1:0.1至1:10，优选地以1:0.2至1:9的混合比(kg/l)混合的混合溶剂，在50～80℃下使用搅拌提取、热水提取、冷浸提取、回流冷却提取或超声波提取等提取方法提取约0.5至48小时，优选地提取1至30小时之后获得提取液，对该提取液进行过滤、减压浓缩或干燥，由此可获得松萝提取物。
在本发明中，人参(Panax ginseng C.A.Meyer)为五加科的多年生草本，多数栽培为药用。人参是在包括韩国和中国的东方各国中长期用作补血强身剂的药草，虽然美国、日本、中国、俄罗斯等地区也有类似于人参的东西，但是在韩国生产的高丽人参，在系统、形态及成分方面上存在差异，高丽人参被认为人参中的第一。根据最近的研究，认定多种药理效果。人参根据加工方法分为多个种类，未加工的人参被称为水参或生参。由于水参的水分含量高，保质期短，因此经过加工过程，提高保存性。不煮熟水参，通过日晒、热风等方法干燥的叫做白参，红参是利用水蒸气煮熟水参而干燥的。
在本发明中，发酵黑参(black ginseng)是指将水参进行蒸熟及干燥而制造的黑参中制备提取物之后发酵的人参。
上述黑参是将虽然与红参制备方法类似，但蒸煮水参而干燥的过程重复1次以上，优选地重复3次以上，最优选地重复9次而制备的，根据人参产业法呈现淡黑褐色或黑茶褐色。据悉，黑参是人参皂苷含量比起水参更增加的人参，人参中不存在的人参皂苷种类大量存在于黑参。
上述黑参提取物是根据常规的提取方法制备的提取物，上述黑参提取物包含通过提取处理获得的提取液、提取液的稀释液或浓缩液、干燥提取液而获得的干燥物、它们的粗纯化物或纯化物。
上述黑参提取物的提取溶剂并不是务必限定于此，但是可以是水、碳原子数1至4的无水或含水低级醇(甲醇、乙醇、丙醇、丁醇等)、上述低级醇与水的混合溶剂、丙酮、乙酸乙酯、氯仿或1,3-丁二醇中的任一个。
作为一个具体例，对于黑参提取物而言，在9次蒸煮及干燥的黑参中添加水或乙醇，在50～80℃下提取3～5小时，减压浓缩而制备。
上述黑参提取物的发酵可利用常规的发酵微生物来实现。这种发酵微生物并不是务必限定于此，但有杆菌(Bacillus)属、乳杆菌(Lactobacillus)属、酵母菌(Saccharomyces)属、曲霉菌(Aspergillus)属等。上述杆菌(Bacillus)属微生物有枯草芽孢杆菌(Bacillus subtilis)、地衣芽孢杆菌(Bacillus lichenformis)等。上述乳杆菌(Lactobacillus)属微生物有嗜酸乳杆菌(Lactobacillus acidophilus)、植物乳杆菌(Lactobacillus plantarum)、短乳杆菌(Lactobacillus brevis)、干酪乳杆菌(Lactobacillus casei)等。上述酵母菌(Saccharomyces)属微生物有酿酒酵母(Saccharomyces cerevisiae)等。上述曲霉菌(Aspergillus)属微生物有白曲菌(Aspergillus kawachii)、泡盛曲霉(Aspergillus awamori)、米曲霉(Aspergillusoryzae)、酱油曲霉(Aspergillus sojae)及宇佐美曲霉(Aspergillus usamii)等。除此之外，还有汉逊酵母(Hansenula polymorpha)、毕赤酵母(Pichia pastoris)、解脂耶氏酵母(Yarrowia lipolytica)等。
上述黑参提取物的发酵物可以是在包含黑参提取物的培养基中接种上述发酵微生物并培养之后获得的培养物或从上述培养物中提取的提取物。并且，上述黑参提取物的发酵物可以是上述的培养物或培养物的提取物的稀释液或浓缩液、干燥提取液而获得的干燥物、它们的粗纯化物或纯化物。上述黑参提取物的发酵物在本说明书中与发酵黑参提取物混合使用。
作为一个具体例，以100分之1的体积比，在包含黑参提取物(Panax ginseng rootextract)的培养基中接种预先培养的杆菌(Bacillus)属微生物，尤其接种从水参中分离的杆菌(Bacillus)属微生物，37℃下培养2天之后，高温高压提取之后，在10000rpm下离心分离10分钟，回收上清液。在回收的上清液中添加作为赋形剂的糊精(Dextrin)，冷冻干燥，制备黑参发酵提取物。
在本发明中，复合物是指天山雪莲提取物、松萝提取物及发酵黑参提取物的混合物。上述混合物均包含制备各成分的提取物之后混合的或者混合2个以上的成分制备提取物的物质。在本说明书中，以与复合物的上述意义相同的意义同样使用混合物、混合提取物及复合提取物。
本发明的上述天山雪莲提取物、松萝提取物及发酵黑参提取物的复合物，相比于各个天山雪莲提取物、松萝提取物及发酵黑参提取物，在因氧化应激引起的细胞老化抑制及晚期糖基化终产物与胶原蛋白的交联切割效果中呈现显著上升的效果。
并且，上述复合物以0.4至0.6:0.9至1.1:0.9至1.1的重量比包含天山雪莲提取物、松萝提取物及发酵黑参提取物，优选地以0.45至0.55:0.95至1.05:0.95至1.05的重量比包含，最优选地以0.5:1:1的重量比包含。当天山雪莲提取物、松萝提取物及发酵黑参提取物的混合物的重量比超过上述限定范围时，减少因氧化应激引起的细胞老化抑制效果，并减少晚期糖基化终产物与蛋白质尤其胶原蛋白的交联切割效果，抗老化效果甚微。
在本发明中，术语“抗老化”是指减少、预防或去除因皮肤细胞的老化或凋亡或外部压力而产生的损伤、细纹或粗纹、皮肤弹性减少、皮肤炎症增加或色素沉着过度的情况。上述“抗老化”在本说明书中可混合使用老化改善或皮肤老化改善。
根据本发明的抗老化用组合物同时具有因皮肤相关细胞例如成纤维细胞的氧化应激引起的细胞老化抑制效果及皮肤内晚期糖基化终产物(Advanced glycation end-products，AGEs)与蛋白质例如胶原蛋白之间的交联切割效果，可有效预防或改善交联或晚期糖基化终产物的蓄积引起的皮肤皱纹生成、皮肤弹性减少、皮肤炎症增加、色素沉着过度等皮肤老化。
作为一个具体实施方式，本发明的上述组合物提供为皮肤老化的预防或改善即抗老化用化妆品组合物。
本发明的抗老化用化妆品组合物中所包含的成分及效果等如上所述，因此省略以下具体说明。
本发明的抗老化用化妆品组合物，以整体化妆品组合物的总重量为基准，将作为有效成分的天山雪莲提取物、松萝提取物及发酵黑参提取物的复合物可包含为0.0001至20.0重量百分比，优选地可包含为0.001至10重量百分比，更优选地可包含为0.001至5重量百分比。
作为本发明的一个具体例，上述化妆品组合物，除了上述天山雪莲提取物、松萝提取物及发酵黑参提取物的混合物以外，还可包含化妆品组合物中通常利用的成分。例如，可包含抗氧化剂、稳定剂、增溶剂、维生素、颜料及香料之类的常规的补助剂及载体。
作为本发明的一个具体例，当本发明的组合物使用为化妆品组合物时，以本领域中通常制备的任何剂型都能制备。例如，能够以溶液、悬浮液、乳浊液、糊剂、啫喱、乳霜、乳液、粉饼、香皂、含表面活性剂洁面乳、油、粉底、乳浊液粉底、蜡粉底或喷剂等剂型化。更详细地，能够以营养霜、收敛化妆水、柔软化妆水、乳液、精华素、营养啫喱或按摩霜等机型进行制备。但是，并不是特别限定于此。
上述化妆品组合物的剂型为糊剂、乳霜或啫喱时，作为载体成分可利用动物性油、植物性油、蜡、石蜡、淀粉、黄芪胶、纤维素衍生物、聚乙二醇、硅、膨润土、二氧化硅、滑石或氧化锌等。
上述化妆品组合物的剂型为粉饼或喷剂时，作为载体成分可利用乳糖、滑石、二氧化硅、氢氧化铝、硅酸钙或聚酰胺粉末，尤其为喷剂时，还可包含氯氟烃、丙烷/丁烷或二甲基醚之类的推进剂。
上述化妆品组合物的剂型为溶液或乳浊液时，作为载体成分可利用溶剂、增溶剂或乳化剂。例如，可利用水、乙醇、异丙醇、碳酸乙酯、乙酸乙酯、苄醇、苯甲酸苄酯,丙二醇,1,3-丁二醇,油、脂肪族甘油酯、聚乙二醇或山梨聚糖的脂肪酸酯。
上述化妆品组合物的剂型为悬浮液时，作为载体成分可利用水、乙醇或丙二醇之类的液态的稀释剂、乙氧基化异硬脂醇、聚氧乙烯山梨醇酯及聚氧乙烯山梨醇酐酯之类的悬浮剂、微晶纤维素、偏氢氧化铝、膨润土、琼脂或黄芪胶等。
上述化妆品组合物的剂型为含表面活性剂的洁面乳时，作为载体成分可利用脂肪醇硫酸盐、脂肪醇醚硫酸盐、磺基琥珀酸单酯、羟乙基磺酸盐、咪唑啉鎓衍生物、甲基牛磺酸盐、肌氨酸盐、脂肪酸酰胺醚硫酸盐、烷基酰胺甜菜碱、脂肪醇、脂肪酸甘油酯、脂肪酸二乙醇酰胺、植物油、羊毛脂衍生物或乙氧基化甘油脂肪酸酯等。
本发明的化妆品组合物同时具有因皮肤相关细胞例如成纤维细胞的氧化应激引起的细胞老化抑制效果及皮肤内晚期糖基化终产物(Advanced glycation end-products，AGEs)与蛋白质之间的交联切割效果，不仅可有效改善基于交联的皮肤老化，而且可预防或改善因AGEs蓄积引起的皮肤皱纹生成、皮肤弹性减少、皮肤炎症增加、色素沉着过度。
另一方面，本发明的天山雪莲提取物、松萝提取物、发酵黑参提取物的复合物是来源于植物而对人体几乎没有副作用的天然提取物，在化妆品、食品、医药品及医药外品中可安全用作有效成分。
发明的效果
根据本发明的天山雪莲提取物、松萝提取物及发酵黑参提取物的复合物同时具有因氧化应激引起的细胞老化抑制效果及晚期糖基化终产物(Advanced glycation end-products，AGEs)与蛋白质之间的交联切割效果，不仅可有效改善因AGEs与蛋白质的交联引起的皮肤老化，而且可预防或改善因AGEs蓄积引起的皮肤皱纹生成、皮肤弹性减少、皮肤炎症增加、色素沉着过度之类的晚期糖基化终产物相关皮肤老化症状。并且，作为本发明的有效成分的天山雪莲提取物、松萝提取物及发酵黑参提取物来源于天然原材料，其没有细胞毒性及皮肤副作用，由此可安全适用于化妆品、食品、医药品及医药外品组合物。
附图说明
图1为对比根据本发明的一实施例制备的天山雪莲提取物、松萝提取物及发酵黑参提取物以0.5:1:1的重量比混合的复合提取物的晚期糖基化终产物与胶原蛋白之间的交联切割效果和提取物各自的效果的图表。
图2为对比根据本发明的一实施例制备的天山雪莲提取物、松萝提取物及发酵黑参提取物以0.5:1:1的重量比混合的复合提取物的细胞老化抑制效果和提取物各自的效果的图表。
具体实施方式
以下，通过实施例更详细说明本发明。这些实施例只是用来更加具体说明本发明，根据本发明的主旨，本发明的范围并不限定于这些实施例，这对于本领域普通技术人员来说是显而易见的。
制备例1.天然提取物的制备
将下列表1中记载的天山雪莲全草、金达莱花、日本薯蓣蔓叶枝、巧克力薄荷叶、松萝、波斯菊花、紫苤蓝球根、猕猴桃果实、茶树叶洗涤剂干燥之后，相对于各植物的100重量百分比加入20～50重量百分比的水，在80℃下提取3小时之后，减压浓缩及粉末化，由此获得提取物。
制备例2.发酵提取物的制备
对于下列表1中记载的发酵黑参、发酵芍药、发酵益母草、发酵鼠尾草、发酵柑橘、发酵覆盆子、发酵蔷薇、发酵桑黄、发酵香菇及发酵柚子而言，将各个天然物洗涤及干燥之后，相对于各植物的100重量百分比，加入20～50重量百分比的水，在80℃下提取3小时之后，减压浓缩及粉末化，由此获得提取物。以100分之1的体积比，在包含各植物提取物的培养基中接种预先培养的杆菌(Bacillus)属微生物，尤其接种从水参中分离的杆菌(Bacillus)属微生物，在37℃下培养2天之后，高温高压提取之后，在10000rpm下离心分离10分钟，回收上清液。在回收的上清液中添加作为赋形剂的糊精(Dextrin)，制备发酵提取物。
制备例3.发酵红茶菇的制备
对于下列表1中记载的发酵红茶菇而言，在包含红茶的培养基中添加预先培养的红茶菇红茶菌(Scoby)，在25℃下培养10天之后，高温高压提取之后，在10000rpm下离心分离10分钟，回收上清液。在回收的上清液中添加作为赋形剂的糊精(Dextrin)，制备发酵提取物。
实施例1.具有抗老化效果的天然物的选定
将上述制备例1的20种天然提取物作为对象，确认晚期糖基化终产物与胶原蛋白之间的交联切割效果及过氧化氢处理引起的成纤维细胞的老化抑制效果，选定效果优秀的天然提取物。
1-1.对于晚期糖基化终产物与胶原蛋白的交联的植物提取物的切割功效评价(invitro)
在涂布胶原蛋白的96孔板(well plate)中分注标记有辣根过氧化物酶(Horseradish peroxidase)的晚期糖基化终产物之后，在37℃下培养(incubation)4小时，将胶原蛋白与晚期糖基化终产物进行交联。在0.05％PBST中洗涤3次，去除不与胶原蛋白粘着的晚期糖基化终产物之后，在37℃下分别将公知为晚期糖基化终产物交联切割剂的ALT-711和上述制备例1的植物提取物处理16小时。在0.05％PBST中洗涤3次，将TMB作为底物(substrate)进行发色之后，在450nm下测定吸光度。由此得出的结果值是将对照组作为100％基准来换算的，其结果示于下列表1中。
1-2.因过氧化氢处理引起的成纤维细胞的老化抑制效果
将人正常成纤维细胞(Human normal fibroblast，ATCC)接种于装有DMEM培养基的6-孔微型板块，使得该细胞成为约1×105个的细胞，在5％浓度的CO2培养基中，37℃培养24小时。然后，将制备例1的试验物质和可诱导氧化应激的过氧化氢(H2O2 300μM)一起溶解于培养基之后处理。72小时之后去除细胞培养上清液，用胰蛋白酶-EDTA处理来取出细胞之后，利用Dojindo公司的SPiDER-βGal对细胞进行15分钟荧光染色，利用流式细胞仪(flowcytometry,FACS Calibur,Becton Dickinson,San Jose,CA)计算细胞。确认表示老化相关β-半乳糖苷酶活性的细胞的比率，来观察细胞老化的变化。由此得出的结果值是将对照组作为100％基准来换算的，其结果示于下列表1中。
表1
如上述表1所示，在总共为20种的植物提取物中，选定晚期糖基化终产物与胶原蛋白之间的交联切割效果和因过氧化氢处理引起的成纤维细胞的老化抑制效果优秀的天山雪莲提取物、松萝提取物、发酵黑参提取物3种。
实施例2.确立呈现晚期糖基化终产物与胶原蛋白之间的交联切割效果和因过氧化氢处理引起的成纤维细胞的老化抑制效果的组成比
上述实施例1中选定的天山雪莲提取物、松萝提取物、发酵黑参提取物的混合物是否呈现抗老化效果的上升作用，对此进行实验。
2-1.混合物的制备
以上述制备例1中获得的天山雪莲提取物、松萝提取物、发酵黑参提取物的多种重量比混合而制备样品。样品的组成比如下列表2所示，分别以10个的组成比进行制备。
表2
| 样品编号 | 天山雪莲提取物 | 松萝提取物 | 发酵黑参提取物 |
| #001 | 1 | 0.5 | 1.5 |
| #002 | 1 | 1 | 1 |
| #003 | 1 | 1.5 | 0.5 |
| #004 | 2 | 0.5 | 0.5 |
| #005 | 2 | 1 | 1 |
| #006 | 2 | 1.5 | 0.5 |
| #007 | 0.5 | 0.5 | 2 |
| #008 | 0.5 | 1 | 1.5 |
| #009 | 0.5 | 1.5 | 1 |
| #010 | 0.5 | 1 | 1 |
2-2.晚期糖基化终产物与胶原蛋白之间的交联切割效果和因过氧化氢处理引起的成纤维细胞的老化抑制效果
通过与上述实施例1-1及实施例1-2相同的方法测定了上述实施例2-1中制备的各样品的晚期糖基化终产物与胶原蛋白之间的交联切割效果和因过氧化氢处理引起的成纤维细胞的老化抑制效果。将其结果示于下列表3中。
表3
如表3所示，确认到以0.5:1:1的重量比混合的样品(#010)相比于其他样品，晚期糖基化终产物与胶原蛋白之间的交联及因过氧化氢处理引起的成纤维细胞的老化显著减少。
因此，当混合处理天山雪莲提取物、松萝提取物及发酵黑参提取物时，相比于仅处理1种单一提取物时呈现复合的老化抑制效果，当天山雪莲提取物、松萝提取物及发酵黑参提取物以0.5:1:1的组成比混合时，确认到呈现同时促进晚期糖基化终产物与胶原蛋白之间的交联切割和因过氧化氢处理引起的成纤维细胞的老化抑制的理想功效。
实施例3.复合提取物(#010)的晚期糖基化终产物与胶原蛋白之间的交联切割效果试验
通过与上述实施例1-1相同的方法，对以0.5:1:1的组成比混合天山雪莲提取物、松萝提取物及发酵黑参提取物的复合提取物(#010)和各提取物的晚期糖基化终产物与胶原蛋白之间的交联切割效果进行测定，将其结果示于图1中。
如图1所示，利用以0.5：1：1的重量比混合天山雪莲提取物、松萝提取物及发酵黑参提取物的样品(#010)处理时，与处理各提取物时相比，不仅显著减少晚期糖基化终产物与胶原蛋白之间的交联，而且呈现复合的交联切割效果。
实施例4.复合提取物(#010)对于因过氧化氢处理引起的成纤维细胞的老化抑制效果测定
通过与上述实施例1-2相同的方法，对以0.5:1:1的组成比混合天山雪莲提取物、松萝提取物及发酵黑参提取物的复合提取物(#010)和各提取物的因过氧化氢处理引起的成纤维细胞的老化抑制效果进行测定，将其结果示于图2中。
如图2所示，对于因过氧化氢处理引起的成纤维细胞的老化抑制效果而言，利用以0.5:1:1的重量比混合天山雪莲提取物、松萝提取物、发酵黑参提取物的样品(#010)处理时，呈现因过氧化氢处理引起的成纤维细胞的老化抑制效果。并且，相比于仅处理1种单一提取物时呈现复合的抑制效果。
实施例5.复合提取物(#010)细胞毒性试验
在上述实施例2中，将晚期糖基化终产物与胶原蛋白之间的交联切割效果和因过氧化氢处理引起的成纤维细胞的老化抑制效果综合性地最优秀的复合提取物(#010)分别以10、50、100、200、500、1000ppm浓度处理成纤维细胞，培养3天之后，通过MTT assay测定存活率。将其结果示于下列表4中。
表4
实验结果确认如下，复合提取物(#010)在500ppm以下浓度中不呈现细胞毒性，而在1000ppm的浓度中细胞存活率降低。
实施例6.有关复合提取物(#010)的皮肤的安全性试验
由于复合提取物(#010)在实施例5的细胞毒性试验中被判明为没有细胞毒性，因此为了确认在实际人体皮肤中是否也安全，执行了皮肤安全性验证试验。
6-1.包含复合提取物(#010)的皮肤外用剂的制备
为了复合提取物(#010)的皮肤安全性试验，制备以下列表5的成分及含量包含复合提取物(#010)的皮肤外用剂之后，执行皮肤安全性和临床功效验证试验。首先，混合纯化水、甘油、丁二醇，在70℃下溶解(水部分)，在70℃下溶解上述3种成分和剩余成分(油部分)。将上述油部分添加到水部分，利用高速搅拌机(Tokushu Kika，Japan)搅拌并乳化，去除起泡之后，室温冷却，由此制备皮肤外用剂。
表5
6-2.皮肤原发刺激试验
将健康的30名成人作为对象，在上臂部位隔天贴敷通过上述6-1的方法制备的皮肤外用剂，如此总共贴9次，贴24小时，来测定了复合提取物(#010)是否刺激皮肤。作为对照组使用了将角鲨烷作为基底不包含复合提取物(#010)的皮肤外用剂。
贴敷方法利用斑试器(Finn chamber，Epitest Ltd.芬兰)，在斑试器滴加上述各皮肤外用剂各15μl之后，贴敷。利用以下数学式1，对每次出现在皮肤的反应程度进行评分，将其结果示于下列表6中。
数学式1
平均反应度＝[[{(反应指数×反应度)/(总受试者数×最高分数(4分))}]×100]/检查次数(9次)
此时，在反应度中，±的分数为1分，+为2分，++为4分，平均反应度小于3时，被判定为安全的组合物。
表6
实验结果，对于对照组和试验组1及试验组2而言，相当于±、+、++的人数分别为0名、0名、0名，不出现反应。根据上述数学式1计算的结果，对照组、试验组1及2的平均反应度均为0.00，均为3以下，由此判断为安全的组合物。
下面，例示用于包含本发明的天山雪莲提取物、松萝提取物、发酵黑参提取物的组合物的制剂例。
制剂例1：化妆品制剂
1-1.爽肤水
表9
| 成分 | 重量百分比 |
| 复合提取物(#010) | 0.18～1.8 |
| 甘油 | 3.0 |
| 丁二醇 | 2.0 |
| 丙二醇 | 2.0 |
| 羧乙烯基聚合物 | 0.1 |
| 乙醇 | 10.0 |
| 三乙醇胺 | 0.1 |
| 防腐剂、微量色素、微量香料及纯化水 | 81～ |
| 总计 | 100.0 |
1-2.精华素
表10
| 成分 | 重量百分比 |
| 复合提取物(#010) | 0.18～1.8 |
| 蜂蜡 | 4.0 |
| 聚山梨醇酯60 | 1.5 |
| 失水山梨醇倍半油酸酯 | 0.5 |
| 液体石蜡 | 5.0 |
| 角鲨烷 | 5.0 |
| 辛酸/癸酸甘油三酯 | 5.0 |
| 甘油 | 3.0 |
| 丁二醇 | 3.0 |
| 丙二醇 | 3.0 |
| 羧乙烯基聚合物 | 0.1 |
| 三乙醇胺 | 0.2 |
| 防腐剂、微量色素、微量香料及纯化水 | 67.9～ |
| 总计 | 100.0 |
1-3.乳液
表11
| 成分 | 重量百分比 |
| 复合提取物(#010) | 0.18～1.8 |
| 蜂蜡 | 10.0 |
| 聚山梨醇酯60 | 1.5 |
| 失水山梨醇倍半油酸酯 | 0.5 |
| 液体石蜡 | 10.0 |
| 角鲨烷 | 5.0 |
| 辛酸/癸酸甘油三酯 | 5.0 |
| 甘油 | 5.0 |
| 丁二醇 | 3.0 |
| 丙二醇 | 3.0 |
| 三乙醇胺 | 0.2 |
| 防腐剂、微量色素、微量香料及微量纯化水 | 55～56.62 |
| 总计 | 100.0 |
1-4.乳霜
表12
| 成分 | 重量百分比 |
| 复合提取物(#010) | 0.18～1.8 |
| 蜂蜡 | 10.0 |
| 聚山梨醇酯60 | 1.5 |
| 失水山梨醇倍半油酸酯 | 0.8 |
| 液体石蜡 | 40.0 |
| 角鲨烷 | 5.0 |
| 辛酸/癸酸甘油三酯 | 4.0 |
| 甘油 | 5.0 |
| 丁二醇 | 3.0 |
| 丙二醇 | 3.0 |
| 三乙醇胺 | 0.2 |
| 防腐剂、微量色素、微量香料及微量纯化水 | 25.7～27.32 |
| 总计 | 100.0 |
1-5.眼霜
表13
| 成分 | 重量百分比 |
| 复合提取物(#010) | 0.18～1.8 |
| 聚乙烯醇 | 13.0 |
| 羧甲基纤维素钠 | 0.2 |
| 尿囊素 | 0.1 |
| 乙醇 | 5.0 |
| 壬基苯基醚 | 0.3 |
| 防腐剂、微量色素、微量香料及微量纯化水 | 79.6～81.22 |
| 总计 | 100.0 |
以上，详细描述本发明的特定部分，这些具体描述仅是优选的实例，本发明的范围并不限定于此，这对于本领域普通技术人员而言是显而易见的。因此，本发明的实质性范围应当根据所附的权利要求和其等同技术方案所定义。
Claims (10)
1.一种抗老化用化妆品组合物，其特征在于，包含天山雪莲提取物、松萝提取物及发酵黑参提取物的复合物作为有效成分。
2.根据权利要求1所述的抗老化用化妆品组合物，其特征在于，所述复合物中，天山雪莲提取物、松萝提取物及发酵黑参提取物以0.4至0.6:0.9至1.1:0.9至1.1的重量比混合。
3.根据权利要求1所述的抗老化用化妆品组合物，其特征在于，相对于组合物总重量，以0.001至20重量百分比的量包含所述复合物。
4.根据权利要求1所述的抗老化用化妆品组合物，其特征在于，所述抗老化通过抑制因氧化应激引起的细胞老化及切割皮肤内的晚期糖基化终产物与蛋白质之间的交联的效果来预防或改善皮肤老化。
5.一种抗老化用外用剂组合物，其特征在于，包含由天山雪莲提取物、松萝提取物及发酵黑参提取物以0.4至0.6:0.9至1.1:0.9至1.1的重量比混合的复合物作为有效成分。
6.根据权利要求5所述的抗老化用化妆品组合物，其特征在于，所述抗老化通过抑制因氧化应激引起的细胞老化及切割皮肤内的晚期糖基化终产物与蛋白质之间的交联而预防或改善皮肤老化。
7.一种疾病的预防或治疗用药学组合物，其特征在于，所述疾病是选自由糖尿病并发症、动脉硬化、肾功能衰竭、类风湿性关节炎及阿尔茨海默病组成的组中的一种以上的疾病，所述药学组合物包含由天山雪莲提取物、松萝提取物及发酵黑参提取物以0.4至0.6:0.9至1.1:0.9至1.1的重量比混合的复合物作为有效成分。
8.根据权利要求7所述的药学组合物，其特征在于，所述疾病通过切割生物体内的晚期糖基化终产物与蛋白质之间的交联而预防或治疗。
9.一种疾病的预防或改善用食品组合物，其特征在于，所述疾病是选自由抗老化或糖尿病并发症、动脉硬化、肾功能衰竭、类风湿性关节炎及阿尔茨海默病组成的组中的一种以上的疾病，所述食品组合物由天山雪莲提取物、松萝提取物及发酵黑参提取物以0.4至0.6:0.9至1.1:0.9至1.1的重量比混合的复合物作为有效成分。
10.根据权利要求9所述的食品组合物，其特征在于，所述抗老化及疾病通过抑制因氧化应激引起的细胞老化及切割晚期糖基化终产物与蛋白质之间的交联而预防或改善。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210069185A KR102617856B1 (ko) | 2021-05-28 | 2021-05-28 | 천산설연, 송라 및 발효 흑삼 추출물을 포함하는 항노화용 조성물 |
| KR10-2021-0069185 | 2021-05-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115400050A true CN115400050A (zh) | 2022-11-29 |
| CN115400050B CN115400050B (zh) | 2024-07-09 |
Family
ID=
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116549361A (zh) * | 2023-07-05 | 2023-08-08 | 西施兰(珠海)医药科技有限公司 | 一种乌洛托品组合物及其制备方法 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110067994A (ko) * | 2009-12-15 | 2011-06-22 | (주)아모레퍼시픽 | 송라추출물을 함유하는 피부외용제 조성물 |
| CN104873558A (zh) * | 2015-06-11 | 2015-09-02 | 北京凯宾鸿生物医药科技有限公司 | 一种高含量人参皂苷的黑参的制备方法 |
| KR20170035691A (ko) * | 2015-09-23 | 2017-03-31 | 코웨이 주식회사 | 꽃송이버섯 균사체를 이용한 송라 발효 추출물을 유효성분으로 함유하는 화장료 조성물 |
| CN108245545A (zh) * | 2016-12-29 | 2018-07-06 | 伽蓝（集团）股份有限公司 | 一种雪莲提取物及其制备方法和应用、含其的皮肤外用剂 |
| CN110494148A (zh) * | 2017-02-09 | 2019-11-22 | 安特瑞珍有限公司 | 将人参/红参及海参复合提取物作为有效成分的布鲁赫膜功能下降相关疾病预防或治疗用组合物 |
| CN111888301A (zh) * | 2020-09-09 | 2020-11-06 | 广州上悦生物科技有限公司 | 一种抗衰老组合物及其应用 |
| CN112516023A (zh) * | 2020-12-09 | 2021-03-19 | 大连普瑞康生物技术有限公司 | 一种含天山雪莲细胞水提取物的抗衰老护肤品 |
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110067994A (ko) * | 2009-12-15 | 2011-06-22 | (주)아모레퍼시픽 | 송라추출물을 함유하는 피부외용제 조성물 |
| CN104873558A (zh) * | 2015-06-11 | 2015-09-02 | 北京凯宾鸿生物医药科技有限公司 | 一种高含量人参皂苷的黑参的制备方法 |
| KR20170035691A (ko) * | 2015-09-23 | 2017-03-31 | 코웨이 주식회사 | 꽃송이버섯 균사체를 이용한 송라 발효 추출물을 유효성분으로 함유하는 화장료 조성물 |
| CN108245545A (zh) * | 2016-12-29 | 2018-07-06 | 伽蓝（集团）股份有限公司 | 一种雪莲提取物及其制备方法和应用、含其的皮肤外用剂 |
| CN110494148A (zh) * | 2017-02-09 | 2019-11-22 | 安特瑞珍有限公司 | 将人参/红参及海参复合提取物作为有效成分的布鲁赫膜功能下降相关疾病预防或治疗用组合物 |
| CN111888301A (zh) * | 2020-09-09 | 2020-11-06 | 广州上悦生物科技有限公司 | 一种抗衰老组合物及其应用 |
| CN112516023A (zh) * | 2020-12-09 | 2021-03-19 | 大连普瑞康生物技术有限公司 | 一种含天山雪莲细胞水提取物的抗衰老护肤品 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116549361A (zh) * | 2023-07-05 | 2023-08-08 | 西施兰(珠海)医药科技有限公司 | 一种乌洛托品组合物及其制备方法 |
| CN116549361B (zh) * | 2023-07-05 | 2023-11-14 | 西施兰（南阳）药业股份有限公司 | 一种乌洛托品组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220161627A (ko) | 2022-12-07 |
| KR102617856B1 (ko) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101086225B1 (ko) | 청미래덩굴 추출물을 유효성분으로 함유하는 화장료 조성물 | |
| CN112569150B (zh) | 包含幼苗人参发酵物的化妆料组合物及其制备方法 | |
| KR102412689B1 (ko) | 한약재의 유효성분을 포함하는 기능성 발효오일 및 제조방법 | |
| CN106821948B (zh) | 将利用银耳菌丝体的松萝发酵提取物作为有效成分的化妆品组合物 | |
| KR102088728B1 (ko) | 식물 복합추출물을 유효성분으로 함유하는 피부 탄력 및 주름 개선용 화장료 조성물 | |
| KR20180048408A (ko) | 쉰다리 전통 발효 기술에 의해 피부 미백 효능이 증진된 삼백초를 함유하는 피부 미백용 화장료 조성물 및 그 제조방법 | |
| KR102499073B1 (ko) | 미세조류추출물 제조방법과 미세조류추출물로부터 수득한 펩타이드복합물을 이용한 주름개선용 화장료 조성물 | |
| KR20190063549A (ko) | 대나무 발효물을 함유하는 화장료 조성물 | |
| KR20070019120A (ko) | 작약 추출물를 유효성분으로 함유하는 피부 주름 개선용화장료 조성물 | |
| KR101308669B1 (ko) | 오크라, 다시마, 참마, 모로헤이야, 연근, 폴리글루탐산을 이용하여 구성된 네바네바컴플랙스를 포함하는 화장료 조성물 | |
| KR101814498B1 (ko) | 유칼립투스 잎과 붉은토끼풀 잎의 혼합 추출물을 함유하는 화장료 조성물 | |
| KR101532001B1 (ko) | 발효 조성물을 함유하는 피부 주름의 예방 또는 개선을 위한 화장품 | |
| KR102350857B1 (ko) | 국화 및 목련 유성온천수 추출물의 유산균 발효물을 함유하는 화장료 조성물 및 그 제조방법 | |
| KR20050039327A (ko) | 예덕나무 추출물을 함유하는 주름 개선 화장료 조성물 | |
| FR2928549A1 (fr) | Utilisation d'un extrait de l'orchidee brassocattleya marcella koss en tant qu'actif pour prevenir ou retarder l'apparition des signes du vieillissement cutane | |
| KR101790185B1 (ko) | 발효콩 추출 분획물을 유효 성분으로 포함하는 화장료 조성물 | |
| KR20210155987A (ko) | 락토바실러스 브레비스 균주로 발효한 해조류 복합 발효 추출물을 유효성분으로 포함하는 피부 탄력 또는 피부 주름 개선, 항산화 및 피부 보습용 조성물 | |
| KR20150081892A (ko) | 돼지감자 추출물을 함유하는 화장료 조성물 | |
| KR101587077B1 (ko) | 피부 생리활성을 가지는 백년초 발효물을 포함하는 조성물 | |
| KR102308756B1 (ko) | 귤껍질 및 칼메그의 혼합추출물을 유효성분으로 함유하는 화장료 조성물 | |
| CN115400050B (zh) | 包含天山雪莲、松萝及发酵黑参提取物的抗老化用组合物 | |
| CN113631227B (zh) | 抗老化剂、抗氧化剂、抗炎剂、及美白剂、以及化妆品 | |
| KR20190049067A (ko) | 커피 실버스킨 및 커피박 추출물을 유효성분으로 함유하는 화장료 조성물 | |
| KR102247966B1 (ko) | 녹두씨, 만주자작나무수액 및 소리쟁이뿌리의 혼합추출물을 함유하는 화장료 조성물 | |
| CN115400050A (zh) | 包含天山雪莲、松萝及发酵黑参提取物的抗老化用组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |